Natixis’s Merck MRK Stock Holding History

Natixis’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-800	Closed	-$69K	–	1262
2022 Q3	$69K	Sell	800 -279	-26%	-$24.9K	﹤0.01%	999
2022 Q2	$99K	Buy	+1,079	New	+$95.7K	﹤0.01%	1053

Other funds holding MRK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Natixis's MRK Position: Q1 2026 in Review

Natixis increased its Merck (MRK) stake by 65% in Q1 2026, buying an estimated $23.2M and bringing the position to 510,056 shares worth $61.4M. The position accounts for 0.22% of the portfolio, ranked #62.

Natixis first reported a position in MRK in Q2 2013 and has held it in 48 quarters since. The position peaked at $275M in Q3 2022. 3,778 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

Natixis held 510,056 shares of Merck worth $61.4M as of Q1 2026.
Natixis bought 201,284 Merck shares in Q1 2026, an estimated $23.2M.
Merck made up 0.22% of Natixis's portfolio in Q1 2026, its #62 holding.
Natixis first reported a position in Merck in Q2 2013 and has held it in 48 quarters since.
Natixis's Merck position peaked at $275M in Q3 2022.
3,778 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.